Table 2 Demographics and clinical characteristics between the immunotherapy responder and non-responder groups
From: Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer
Characteristics | Responder | Non-responder | Total | P-value |
|---|---|---|---|---|
No | 8 (72.7) | 3 (27.3) | 11 (100.0) | Â |
Age | 63.0 (54.5, 73.8) | 62.0 (50.0, 62.0) | 63.0 (54.0, 74.0) | 0.840 |
Gender | Â | Â | Â | 0.491 |
 Male, n (%) | 7 (87.5) | 2 (66.7) | 9 (81.8) |  |
 Female, n (%) | 1 (12.5) | 1 (33.3) | 2 (18.2) |  |
Smoking history | Â | Â | Â | 0.179 |
 Current or former, n (%) | 7 (87.5) | 2 (66.7) | 9 (81.8) |  |
 Never, n (%) | 1 (12.5) | 1 (33.3) | 2 (18.2) |  |
Pack-years | 35.0 (30.0, 40.0) | 41.5 (33.0, 41.5) | 35.0 (30.0, 45.0) | 0.526 |
Neutrophil–lymphocyte ratio | 2.63 (2.13, 4.36) | 1.98 (1.86, 1.98) | 2.27 (1.98, 3.76) | 0.133 |
PD-L1 ≥ 10% | 2 (25.0) | 1 (33.3) |  |  |
PD-L1 < 10% | 6 (75.0) | 2 (66.7) |  |  |
Stage | Â | Â | Â | 0.361 |
 I/II/III/IV, n | 0/0/4/4 | 0/0/1/2 | 0/0/5/6 |  |
Pathologic diagnosis | Â | Â | Â | 0.661 |
 Adenocarcinoma, n (%) | 6 (75.0) | 2 (66.7) | 8 (72.7) |  |
 Squamous cell carcinoma, n (%) | 2 (25.0) | 1 (33.3) | 3 (27.3) |  |